Literature DB >> 18024859

Germline pharmacogenetics of tamoxifen response: have we learned enough?

Zeruesenay Desta, David A Flockhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18024859      PMCID： PMC2764520          DOI： 10.1200/JCO.2007.13.4957

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

Review 1.  Hot flushes.

Authors:  Vered Stearns; Lynda Ullmer; Juan F López; Yolanda Smith; Claudine Isaacs; DanielF Hayes
Journal:  Lancet       Date:  2002-12-07       Impact factor: 79.321

2.  Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

Authors:  E A Lien; E Solheim; S Kvinnsland; P M Ueland
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

3.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

Authors:  V C Jordan; M M Collins; L Rowsby; G Prestwich
Journal:  J Endocrinol       Date:  1977-11       Impact factor: 4.286

4.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

5.  Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

Authors:  D W Robertson; J A Katzenellenbogen; D J Long; E A Rorke; B S Katzenellenbogen
Journal:  J Steroid Biochem       Date:  1982-01       Impact factor: 4.292

6.  Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.

Authors:  Michael D Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P Trebley; James Michael Rae; Ross V Weatherman; Zeruesanay Desta; David A Flockhart; Todd C Skaar
Journal:  Breast Cancer Res Treat       Date:  2004-05       Impact factor: 4.872

7.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.

Authors:  E Coezy; J L Borgna; H Rochefort
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

8.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Authors:  Werner Schroth; Lydia Antoniadou; Peter Fritz; Matthias Schwab; Thomas Muerdter; Ulrich M Zanger; Wolfgang Simon; Michel Eichelbaum; Hiltrud Brauch
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 9.  Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

10.  Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Authors:  Zeruesenay Desta; Bryan A Ward; Nadia V Soukhova; David A Flockhart
Journal:  J Pharmacol Exp Ther       Date:  2004-05-24       Impact factor: 4.030
View more
  11 in total

Review 1.  Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal.

Authors:  Subhojit Dey
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 2.  Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.

Authors:  Richard R Love
Journal:  Oncology (Williston Park)       Date:  2010-04-15       Impact factor: 2.990

3.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

Review 4.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 5.  Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors:  Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

6.  Defining a global research agenda for breast cancer.

Authors:  Richard R Love
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

Review 7.  Clinically available pharmacogenomics tests.

Authors:  D A Flockhart; T Skaar; D S Berlin; T E Klein; A T Nguyen
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

8.  Global cancer research initiative.

Authors:  Richard R Love
Journal:  Cancer Manag Res       Date:  2010-05-03       Impact factor: 3.989

9.  Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.

Authors:  Ke-Da Yu; A-Ji Huang; Zhi-Ming Shao
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

10.  Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.

Authors:  N L Henry; A Nguyen; F Azzouz; L Li; J Robarge; S Philips; D Cao; T C Skaar; J M Rae; A M Storniolo; D A Flockhart; D F Hayes; V Stearns
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.